PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30872078-0	2019	Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction.	Vemurafenib	52-63	cyclin dependent kinase 1	Homo sapiens	89-93	
30872078-3	2019	We found that CDK1 is stably activated in the vemurafenib-resistant (VR) colon cancer sublines that we established, indicating that CDK1 activation is responsible for vemurafenib resistance.	Vemurafenib	46-57	cyclin dependent kinase 1	Homo sapiens	14-18	
30872078-3	2019	We found that CDK1 is stably activated in the vemurafenib-resistant (VR) colon cancer sublines that we established, indicating that CDK1 activation is responsible for vemurafenib resistance.	Vemurafenib	46-57	cyclin dependent kinase 1	Homo sapiens	132-136	
30872078-3	2019	We found that CDK1 is stably activated in the vemurafenib-resistant (VR) colon cancer sublines that we established, indicating that CDK1 activation is responsible for vemurafenib resistance.	Vemurafenib	167-178	cyclin dependent kinase 1	Homo sapiens	14-18	
30872078-3	2019	We found that CDK1 is stably activated in the vemurafenib-resistant (VR) colon cancer sublines that we established, indicating that CDK1 activation is responsible for vemurafenib resistance.	Vemurafenib	167-178	cyclin dependent kinase 1	Homo sapiens	132-136	
30872078-7	2019	This study reveals that CDK1 activation induces vemurafenib resistance and that AD is a promising therapeutic strategy for colon cancer both as a single agent and in combination with vemurafenib.	Vemurafenib	48-59	cyclin dependent kinase 1	Homo sapiens	24-28